long intergenic non-protein coding RNA 1585Genealiases: []
Q-omics provides the consensus-scored LINC01585 profile across patient tissues and cancer cell-line models. LINC01585 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01585 is differentially expressed in 9, with the highest sampling consensus in READ. Additionally, LINC01585 RNA expression shows 14,698 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, READ, and UVM as cancer lineages where LINC01585 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01585 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01585 survival associations across molecular data types. LINC01585 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01585 RNA expression–survival associations across cancer types. High LINC01585 expression shows unfavorable associations in KIRC, LGG, UCEC and KIRP, but favorable associations in DLBC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01585 RNA expression.
This table summarizes LINC01585 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01585. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01585 shows higher tumor expression in READ, COAD, CHOL, LUSC, LUAD and ESCA. The READ box plot shows higher LINC01585 RNA expression in tumor versus normal tissue (log2 FC = +0.188, t-test p = .001).
This table shows molecular features associated with LINC01585 in patient tissues and cancer cell lines. In patient samples, LINC01585 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
